Protalix Biotherapeutics Stock Pattern Recognition Piercing Pattern
| PLX Stock | USD 2.90 0.02 0.69% |
| Symbol |
Recognition |
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was eleven with a total number of output elements of fifty. The function did not return any valid pattern recognition events for the selected time horizon. The Piercing pattern may indicate Protalix Biotherapeutics low bullish reversal trend.
Protalix Biotherapeutics Technical Analysis Modules
Most technical analysis of Protalix Biotherapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Protalix from various momentum indicators to cycle indicators. When you analyze Protalix charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Protalix Biotherapeutics Inc
Protalix Biotherapeutics is scheduled to announce its earnings tomorrow.Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company was founded in 1993 and is based in Hackensack, New Jersey. Protalix Biotherapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 202 people. This overview emphasizes how Protalix Biotherapeutics compares to peers on valuation quality and operating consistency. Current metrics include P/B of 4.38, profit margin of 8.72%. Protalix Biotherapeutics has market cap of 233.22 M, ROE of 12.64%.
Methodology
Unless otherwise specified, financial data for Protalix Biotherapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Protalix (USA Stocks:PLX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Protalix Biotherapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Protalix Biotherapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Align your values with your investing style
Using Protalix Biotherapeutics inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Thematic Opportunities
Explore Investment Opportunities
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Warren Buffett Holdings Invested few shares | |
 | Hedge Favorites Invested over 60 shares | |
 | Advertising Invested few shares | |
 | Macroaxis Index Invested few shares | |
 | Driverless Cars Invested over 200 shares | |
 | Dividend Beast Invested over 40 shares | |
 | FinTech Invested over 20 shares | |
 | Momentum Invested over 200 shares | |
 | Disruptive Technologies Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Investor Favorites Invested over 20 shares | |
 | Macroaxis Picks Invested few shares | |
More Resources for Protalix Stock Analysis
A comprehensive view of Protalix Biotherapeutics starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Protalix Biotherapeutics Stock. Key reports that frame Protalix Biotherapeutics Stock are listed below:Protalix Biotherapeutics has market cap of 233.22 M, operating margin of 11.94%, ROE of 12.64%. Review Your Equity Center for broader portfolio context. This reflects a position in Protalix Biotherapeutics in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Our How to Invest in Protalix Biotherapeutics guide provides practical guidance on trading Protalix Stock.Analysis related to Protalix Biotherapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Quarterly Earnings Growth -0.01 | Earnings Share 0.08 | Revenue Per Share | Quarterly Revenue Growth -0.01 | Return On Assets |
Protalix Biotherapeutics market price can diverge from book value, the accounting figure shown on Protalix balance sheet. Protalix Biotherapeutics' market capitalization is 233.22 M. With a P/B ratio of 4.38, the market values Protalix Biotherapeutics well above its book equity. Enterprise value stands at 210.42 M. Intrinsic value is an analytical estimate of Protalix Biotherapeutics' underlying worth that can differ from price and book value. Valuation methods help interpret those gaps.
It is useful to distinguish Protalix Biotherapeutics' value from its trading price, which are computed with different methods. For Protalix Biotherapeutics, key inputs include a P/B ratio of 4.38, a profit margin of 8.72%, ROE of 12.64%, and revenue of 53.4 M. By contrast, market price reflects the level where buyers and sellers transact.